Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25088414 | 1.00 | MAP4K1 (0.46) | MAP4K1TRPA1IRAK4CYP1A2CYP2D6 | |
| SCHEMBL29317874 | 0.82 | MAP4K1 (0.46) | MAP4K1TRPA1IRAK4CYP1A2CYP2D6 | |
| SCHEMBL30217562 | 0.80 | MAP4K1 (0.32) | MAP4K1 | |
| SCHEMBL25088065 | 0.80 | MAP4K1 (0.32) | MAP4K1 | |
| SCHEMBL1935022 | 0.79 | MAP4K1 (0.45) | MAP4K1TRPA1IRAK4CYP1A2CYP2D6 | |
| SCHEMBL21954726 | 0.78 | LRRK2 (0.38) | TRPA1AKT1LRRK2CHEK1MAPK1 | |
| SCHEMBL15359645 | 0.75 | CHEK1 (0.36) | MAP4K1PDPK1LRRK2CHEK1MAPK1 | |
| SCHEMBL2112465 | 0.75 | CHEK1 (0.51) | TRPA1IRAK4LRRK2CHEK1JAK3 | |
| SCHEMBL30689578 | 0.74 | MAP4K1 (0.31) | MAP4K1 | |
| SCHEMBL31318237 | 0.74 | CYP2A6 (0.45) | LRRK2CHEK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368640-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-12-04 | — | — | US | disclosed |
| EP-4598918-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-08-13 | — | — | EP | disclosed |
| EP-4540247-A1 | MULTI-KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540246-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-04-23 | — | — | EP | disclosed |
| CN-119137123-A | Multi-kinase degradants, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119032093-A | Multi-kinase inhibitors, compositions and methods of use | 百放开曼有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4392420-A1 | HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-07-03 | — | — | EP | disclosed |
| EP-4392417-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024073871-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-04-11 | — | — | WO | disclosed |
| CN-117858874-A | HPK1 degrading agents, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023246490-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023246491-A1 | MULTI-KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023245327-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023245329-A1 | MULTI-KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023025091-A1 | HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023023941-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPKI DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023025092-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023023942-A1 | HPK1 INHIBITORS, COMPOSITIONS COMPRISING HPK1 INHIBITOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (CAYMAN) (KY) | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368640-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | MAP4K1, MAP4K4, MAP4K5 | MAP4K1 1/4885TRPA1 4749/4885IRAK4 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.